Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objectives are to assess the antiviral activity, clinical safety and tolerability
parameters of albuvirtide/3BNC117 combination therapy in reducing HIV-1 viral load during the
1-week induction period treatment period.